1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Nunzia Pharmaceutical Company

Nunzia Pharmaceutical Company

NUNZ
Nunzia Pharmaceutical CompanyUS flagOther OTC
0.00
USD
- -
- -
43,451.00Market Cap
Nunzia Pharmaceutical Company
NUNZ
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2004
2005
2006
2007
2008
2009
2017
2018
2019
2020
2021
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-29.55
-20.28
-10.14
-9.21
- -
-40.45
-0.62
-0.88
- -
-0.35
-0.26
-0.22
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-2,312.95
-2,330.09
-2,337.25
-2,344.96
-2,353.3
-23,630.73
-6.27
-7.16
- -
-0.35
-0.59
-0.46
Book Value per Share
-196.35
-208.67
-215.83
-223.54
-231.88
-2,412.57
-13.11
-14
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
253
285
305
434
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
-101
-78
-97
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-2
-3
-3
-4
-4
-4
- -
- -
- -
- -
- -
- -
Working Capital
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
-3
-3
-3
-4
-4
-4
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'22
Jun'22
Sep'22
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
434
434
435
Market Capitalization
119
269
282

Working Capital

FRC

•

in mil. unless spec.
Mar'22
Jun'22
Sep'22
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.42%
8.64%
58.53%
Free Cash Flow
- -
- -
168.71%
Net Income, GAAP
- -
60,050.37%
-22.72%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
-0.35
2021
- -
- -
- -
- -
-0.26
2022
-0.04
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Similar Companies
Cellular Goods PLC (CBX.L)
Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A (300026.SZ)
AIxCrypto Holdings, Inc. (AIXC)
Leafly Holdings, Inc. (LFLY)
Rest Ez Inc. (RTEZ)
Biofrontera AG (0DOL.L)
Business
Nunzia Pharmaceutical Company Nunzia Pharmaceutical Company operates as a pharmaceutical and nutraceutical company focused on developing and distributing therapies for behavioral symptoms associated with autism spectrum disorders, fragile X syndrome, ADHD, PTSD, and related anxiety-based conditions. The company manufactures, markets, and distributes its flagship product Nunzia, a nutraceutical supplement comprising a blend of 16 vitamins, minerals, and herbs including adaptogenic ingredients such as Rhodiola Rosea Root and Ashwagandha Root that target the hippocampus region of the brain to enhance sensory, social, and daily living skills; improve attention span, memory retention, focus, comprehension, and learning; and reduce anxiety, stress, fixations, fidgeting, and distractions, with products segmented into formulations for adults, kids, and teens offered through wholesalers and its website nunziapharma.com. Founded in 1986 and headquartered in Long Beach, California, the company changed its name from Arizona Gold and Onyx Mining Company in February 2018 to reflect its pivot to the healthcare sector serving patients and healthcare professionals primarily in the United States. No major acquisitions, partnerships, funding rounds, new product launches, or strategic expansions have been reported in the last one to two years.